More than a dozen companies are developing dual-targeting antibodies that block PD-1 or PD-L1 and VEGF in one way or another. Akeso, a Guangdong, China-based cancer drug developer, originally ...

For the first time, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody has shown that it can extend ...

For patients with low PD-L1 expression or those who are resistant to PD-1 monotherapy, cadonilimab provides significant clinical benefits over current treatment options.

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.

Bristol Myers Squibb’s partnership with BioNTech makes it the third big pharma company to strike a deal to gain access to a PD-L1/PD-1 and VEGF bispecific antibody with potential use in drug ...

Established market size for PD-1 and PD-L1 checkpoint inhibitor antibodies; Business deals with economic terms: spin-offs, financing, licensing; mergers & acquisitions, company valuation.

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in ...

Akeso, Sino Biopharm’s Anniko enters crowded PD-1 market with FDA approval in head and neck cancer subtype By Angus Liu Apr 25, 2025 10:55am Akeso Biopharma PD-1/L1 FDA approvals head and neck ...

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in ...